$0.51
Our top picks for where to buy 23Andme Holding stock
- Earn 5.25% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Trade stocks, bonds, options, ETFs, crypto, Treasurys, collectibles, royalties
- Earn 5.1% APY on your cash
- Earn a $0.18 rebate on options, with no commissions and no per-contract fees
- Trade stocks, options and ETFs without commissions
- Innovative social trading features
- FINDER EXCLUSIVE: Get a guaranteed $15 bonus when you sign up and deposit $100
How to buy 23Andme Holding stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ME. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy 23Andme Holding stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
23Andme Holding is a diagnostics & research business based in the US. 23Andme Holding shares (ME) are listed on the NASDAQ and all prices are listed in US Dollars. 23Andme Holding employs 769 staff and has a trailing 12-month revenue of around $248 million.
23Andme Holding stock price (NASDAQ: ME)
Use our graph to track the performance of ME stocks over time.23Andme Holding shares at a glance
Latest market close | $0.49 |
---|---|
52-week range | $0.40 - $2.32 |
50-day moving average | $0.62 |
200-day moving average | $1.04 |
Wall St. target price | $1.43 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.11 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy 23Andme Holding stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
23Andme Holding price performance over time
Historical closes compared with the close of $0.4878 from 2024-03-26
1 week (2024-03-21) | 11.57% |
---|---|
1 month (2024-02-28) | -20.62% |
3 months (2023-12-28) | -47.44% |
6 months (2023-09-28) | -52.18% |
1 year (2023-03-28) | -77.62% |
---|---|
2 years (2022-03-28) | -86.99% |
3 years (2021-03-26) | 10.3 |
5 years (2019-03-24) | N/A |
23Andme Holding financials
Revenue TTM | $248 million |
---|---|
Gross profit TTM | $132.9 million |
Return on assets TTM | -26.17% |
Return on equity TTM | -92.53% |
Profit margin | -210.48% |
Book value | $0.78 |
Market Capitalization | $235.6 million |
TTM: trailing 12 months
23Andme Holding share dividends
We're not expecting 23Andme Holding to pay a dividend over the next 12 months.
23Andme Holding share price volatility
Over the last 12 months, 23Andme Holding's shares have ranged in value from as little as $0.4012 up to $2.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 23Andme Holding's is 1.286. This would suggest that 23Andme Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
23Andme Holding overview
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses.
Frequently asked questions
What percentage of 23Andme Holding is owned by insiders or institutions?Currently 3.943% of 23Andme Holding shares are held by insiders and 43.078% by institutions. How many people work for 23Andme Holding?
Latest data suggests 769 work at 23Andme Holding. When does the fiscal year end for 23Andme Holding?
23Andme Holding's fiscal year ends in March. Where is 23Andme Holding based?
23Andme Holding's address is: 349 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is 23Andme Holding's ISIN number?
23Andme Holding's international securities identification number is: US90138Q1085
More guides on Finder
-
10 best brokerage account bonuses of 2024
Explore the best bonuses for opening a new brokerage account.
-
11 best trading platforms for beginners 2024
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
9 best discount brokers of 2024
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
12 best stock trading apps of 2024
These are the best stock trading apps for 2024, according to Finder’s analysis.
-
11 best brokerage accounts of 2024
These are the best brokers of 2024 according to Finder’s comprehensive review.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to invest $20K in 2024
Consider investing your $20,000 into various assets including stocks, ETF and REITs.
-
How to invest $50K in 2024
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.
-
J.P. Morgan Self-Directed Investing review 2024
Pros, cons and ways to invest with JPMorgan’s Self-Directed and Automated Investing products.
Ask a Question